The current status, challenges, and future developments of new tuberculosis vaccines
- 14 May 2018
- journal article
- review article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 14 (7), 1697-1716
- https://doi.org/10.1080/21645515.2018.1458806
Abstract
Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guerin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment.Keywords
Funding Information
- Serious Infectious Diseases Special Foundation of China (2012ZX10003008002)
- WHO IVR Steering Committee (V25-181-202)
- Key Subject Foundation of the 309th Hospital of Chinese PLA (2016-ZD-001)
- Medical Science and Technology Youth Cultivation Program of PLA (16QNP075)
- Outstanding Talent Training Project of Beijing (2016000057592G265)
- National Nature and Science Foundation of China (30070730)
This publication has 199 references indexed in Scilit:
- A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive AdultsJournal of Clinical Immunology, 2013
- Nonclinical Development of BCG Replacement Vaccine CandidatesVaccines, 2013
- A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosisNature Medicine, 2011
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosisScience Translational Medicine, 2010
- Potential role for ESAT6 in dissemination ofM.âtuberculosisvia human lung epithelial cellsMolecular Microbiology, 2009
- Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primatesVaccine, 2009
- A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human VolunteersThe Journal of Infectious Diseases, 2008
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South AfricaThe Journal of Infectious Diseases, 2008
- Host Innate Immune Response to Mycobacterium tuberculosisJournal of Clinical Immunology, 2007
- Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosisNature Medicine, 2003